Drug Interactions and Adverse Drug Reactions Study in HIV/AIDS Patients with Tuberculosis at Dr. Hasan Sadikin Hospital Bandung

  • ALEXANDRA VANIA ANDI INSTITUT TEKNOLOGI BANDUNG
  • LIA AMALIA RSUP Dr. Hasan Sadikin Bandung
  • RUDI WISAKSANA RSUP Dr. Hasan Sadikin Bandung

Abstract

HIV/AIDS and tuberculosis require combination therapy that can lead to drug interactions and unwanted drug effects or adverse drug reactions (ADRs). This study was aimed to determine the potential drug interactions, estimate the occured ADRs and provide treatment recommendations for HIV/AIDS patients with tuberculosis. This research was a descriptive study which was conducted retrospectively in forty eight HIV/AIDS patients with tuberculosis receiving treatments in the Teratai clinic, Dr. Hasan Sadikin Bandung Hospital in 2013. From these forty eight patients, there were 109 incidences of potential drug interactions with major significance, 299 incidence of with moderate significance and 58 with minor significance. Estimated ADRs with the greatets number found in this study was 8 incidences of gastrointestinal disorders, 5 incidences of drug eruption, 5 drug-induced liver injury (DILI) incidences and 4 peripheral neuropathy incidences. Patients receiving category 1 tuberculosis therapy was recommended to use tenofovir, lamivudine, and efavirenz as antiretroviral therapy, whereas patients receiving category 2 tuberculosis therapy was recommended to use zidovudine, lamivudine, and efavirenz.

References

1. World Health Organization. Global health observatory: Adult HIV Prevalence (15-49 years) 2012. WHO Region; 2012. Diambil dari http://www.who.int/gho/ hiv/en/. Diakses tanggal 24 Mei, 2013.
2. Departemen Kesehatan Republik Indonesia. Pedoman nasional penanggulangan tuberkulosis. Ed. 2. Jakarta: Departemen Kesehatan Republik Indonesia; 2008. 13-37.
3. World Health Organization. HIV-associated TB facts 2013; 2013. Diambil dari http://www.who.int/ tb/challenges/hiv/tbhiv_factsheet_2013_web.pdf. Diakses tanggal 24 Mei, 2014.
4. American Society of Consultant Pharmacists. When Medicine Hurts; 2013. Diambil dari https://www.ascp. com/articles/when-medicine-hurts-silent-epidemic. Diakses 8 Desember, 2013.
5. Baxter K.(ed). Stockley’s drug interaction. 8th Ed.
220-221, 302, 308-311, 320, 327-328, 342, 595-596, 726, 729-730, 736, 782-785, 790- 795, 800-802, 806- 807, 832, 1061, 1260.
6. Tatro DS. Drug interaction facts. St. Louis, Missouri: Wolters Klower Health; 2008. 19, 21, 52, 205-206, 240, 246, 254, 469, 481, 728, 899, 901, 914, 1008, 1136, 1178, 1329, 1358, 1689, 1749-1750.
7. McEvoy GK (ed). AHFS drug information essentials. Bethesda, Maryland: American Society of Health- System Pharmacists; 2011. html version.
8. Drug Interactions Checker. Diambil dari http://www. drugs.com/drug_interactions.php. Diakses tanggal 15 Mei, 2014.
9. Kementerian Kesehatan Republik Indonesia. Pedoman nasional tatalaksana klinis infeksi HIV dan terapi antiretroviral pada orang dewasa. Jakarta: Kementerian Kesehatan Republik Indonesoa; 2012. 1-94.
10. Kwara A, Flanigan TP, Carter EJ. Highly active antiretroviral therapy (HAART) in adults with tuberculosis: Current status. International Journal of Tuberculosis and Lung Disease. 2005. 248-57.
Published
2015-04-30
How to Cite
ANDI, ALEXANDRA VANIA; AMALIA, LIA; WISAKSANA, RUDI. Drug Interactions and Adverse Drug Reactions Study in HIV/AIDS Patients with Tuberculosis at Dr. Hasan Sadikin Hospital Bandung. JURNAL ILMU KEFARMASIAN INDONESIA, [S.l.], v. 13, n. 1, p. 82-88, apr. 2015. ISSN 2614-6495. Available at: <http://jifi.farmasi.univpancasila.ac.id/index.php/jifi/article/view/129>. Date accessed: 05 nov. 2024.
Citation Formats
Issue
Vol 13 No 1 (2015): JIFI
Section
Articles
License

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.